Tubridy Karen L 4
4 · Akebia Therapeutics, Inc. · Filed Dec 13, 2018
Insider Transaction Report
Form 4
Tubridy Karen L
SVP, Chief Development Officer
Transactions
- Tax Payment
Common Stock
2018-12-12$8.94/sh−11,928$106,636→ 30,229 total
Footnotes (1)
- [F1]Includes 639 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018.